RARA and Obesity: Despite extensive historical and recent evidence that (1) vitamin A metabolism is disturbed in obesity and NAFLD and (2) vitamin A metabolites, especially atRA and synthetic RAR ligands, have beneficial effects on hepatic lipid metabolism and obesity-induced NAFLD in animal models, no clinical trials are ongoing to evaluate their therapeutic potential in patients.